Back to Search
Start Over
Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis.
- Source :
-
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1451-1457. - Publication Year :
- 2024
-
Abstract
- Background: The high mortality of systemic anthrax is likely a consequence of the severe central nervous system inflammation that occurs in anthrax meningitis. Effective treatment of such infections requires, at a minimum, adequate cerebrospinal fluid (CSF) antimicrobial concentrations.<br />Methods: We reviewed English medical literature and regulatory documents to extract information on serum and CSF exposures for antimicrobials with in vitro activity against Bacillus anthracis. Using CSF pharmacokinetic exposures and in vitro B. anthracis susceptibility data, we used population pharmacokinetic modeling and Monte Carlo simulations to determine whether a specific antimicrobial dosage would likely achieve effective CSF antimicrobial activity in patients with normal to inflamed meninges (ie, an intact to markedly disrupted blood-brain barrier).<br />Results: The probability of microbiologic success at achievable antimicrobial dosages was high (≥95%) for ciprofloxacin, levofloxacin (500 mg every 12 hours), meropenem, imipenem/cilastatin, penicillin G, ampicillin, ampicillin/sulbactam, doxycycline, and minocycline; acceptable (90%-95%) for piperacillin/tazobactam and levofloxacin (750 mg every 24 hours); and low (<90%) for vancomycin, amikacin, clindamycin, and linezolid.<br />Conclusions: Prompt empiric antimicrobial therapy of patients with suspected or confirmed anthrax meningitis may reduce the high morbidity and mortality. Our data support using several β-lactam-, fluoroquinolone-, and tetracycline-class antimicrobials as first-line and alternative agents for treatment of patients with anthrax meningitis; all should achieve effective microbiologic exposures. Our data suggest antimicrobials that should not be relied on to treat suspected or documented anthrax meningitis. Furthermore, the protein synthesis inhibitors clindamycin and linezolid can decrease toxin production and may be useful components of combination therapy.<br />Competing Interests: Potential conflicts of interest . J. S. B. is supported by an NICHD grant (1 R01 HD095547-01). J. B. B. is supported by NIAID grants (R01 AI130185 and R01 AI136803). K. H., C. I., E. H., and P. Y. are career officers with the CDC. J. B. reports consulting fees from MicuRx Pharmaceuticals Inc, Aerovate Therapeutics, and Lupin and honorarium for a lecture under T32 (William Shafer, Emory) on antimicrobial pharmacology. A. W. K. reports stock from Pfizer, Johnson & Johnson, and AbbVie. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.<br /> (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.)
- Subjects :
- Humans
Monte Carlo Method
Microbial Sensitivity Tests
Bacillus anthracis drug effects
Anthrax drug therapy
Meningitis, Bacterial drug therapy
Meningitis, Bacterial microbiology
Meningitis, Bacterial cerebrospinal fluid
Anti-Bacterial Agents pharmacokinetics
Anti-Bacterial Agents administration & dosage
Anti-Bacterial Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1537-6591
- Volume :
- 78
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publication Type :
- Academic Journal
- Accession number :
- 38412060
- Full Text :
- https://doi.org/10.1093/cid/ciae093